Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBIT Margin (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EBIT Margin for 3 consecutive years, with 205.18% as the latest value for Q1 2025.

  • Quarterly EBIT Margin changed N/A to 205.18% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 1384.61% through Dec 2025, changed N/A year-over-year, with the annual reading at 1384.61% for FY2025, N/A changed from the prior year.
  • EBIT Margin for Q1 2025 was 205.18% at Centessa Pharmaceuticals, down from 1368.79% in the prior quarter.
  • The five-year high for EBIT Margin was 4138.78% in Q2 2022, with the low at 205.18% in Q1 2025.
  • Average EBIT Margin over 3 years is 2097.27%, with a median of 1919.14% recorded in 2023.
  • Peak annual rise in EBIT Margin hit -51968bps in 2023, while the deepest fall reached -221964bps in 2023.
  • Over 3 years, EBIT Margin stood at 1888.47% in 2022, then dropped by -28bps to 1368.79% in 2023, then crashed by -115bps to 205.18% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 205.18%, 1368.79%, and 1582.41% for Q1 2025, Q4 2023, and Q3 2023 respectively.